Breast Cancer
Share this page:
Conclusion
The American Cancer Society estimated that 184,450 new cases of invasive breast cancer were diagnosed and 40,930 died of breast cancer in the United States in 2008. Approximately 67,770 women were diagnosed with carcinoma in situ of the breast during the same year. Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death.
The incidence of breast cancer has increased steadily in the United States over the past few decades, but breast cancer mortality appears to be declining, suggesting a benefit from early detection and more effective treatment.
CyberKnife® treatment enables patients to undergo their radiotherapy treatment and immediately resume normal daily activities. The treatment requires minimal or no sedation and has a low risk of complications. It is completed in a period of 1-2 weeks with 10 treatments lasting approximately one hour each. The treatment is virtually painless.
The IRB approved protocol developed by CyberKnife Centers of San Diego uses CyberKnife® as a method to treat breast cancer following breast conserving surgery.
To find out if you or your patients can benefit from this study, please contact us by calling any of our numbers listed below or by filling out our contact form.
CyberKnife® allows superior dose conformity to the target
sparing normal structures
Gina J. Mansy, M.D. and Huan B. Giap, M.D. – Radiation Oncologists